ArticleCells2026
Smad2 Preserves Corneal Stromal Homeostasis by Restraining Profibrotic Smad3/YAP/TEAD2 Transcriptional Program.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Corneal transparency depends on quiescence of stromal cells derived from neural crest cells and a well-controlled extracellular matrix. Disruption of this homeostasis causes fibrotic scarring, a leading cause of blindness. Transforming growth factor-β/Smad3 signaling drives corneal fibrogenesis, but the distinct roles of Smad2 versus Smad3 remain unclear. Smad2 ablation in neural crest cells using Wnt1-Cre mice triggers spontaneous severe corneal opacification along with massive stromal hypercellularity and fibrosis. The fibrotic phenotype occurs in the absence of injury, indicating that Smad2 is essential for balancing Smad3 activity in driving fibrotic signaling. Single-cell RNA sequencing and virtual knockout of Smad2 reveal prominent activation of Smad3-Yes-associated protein (YAP)/TEAD2-transcriptional program in Smad2-null corneas. Biochemical assays confirm that Smad2 loss results in increased Smad3 phosphorylation and formation of nuclear Smad3-YAP-TEAD2 complex. This trimeric complex induces the expression of collagen I, connective tissue growth factor, and cyclin D1. Importantly, pharmacologic inhibition of YAP/TEAD interaction with verteporfin blocks stromal hyperplasia and corneal fibrosis by suppressing the expression of fibrotic and cell cycle genes, which lead to restoration of corneal transparency in Smad2-neural crest-deficient mice. Our findings reveal a unique convergence of YAP/TEAD and TGF-β/Smad3 signaling that can be targeted with verteporfin to prevent corneal scarring and blindness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.